immune system
|
|
• decrease in accumulation of double-negative T cells in the spleen compared to Faslpr homozygotes
|
|
|
• decrease in proportion of CD4+ T cells expressing CD44, both in the lymph node and spleen compared to Faslpr homozygotes
|
|
|
• spleen weight is decreased compared to Faslpr homozygotes
|
|
|
• general B cell activation is inhibited compared to Faslpr homozygotes, as indicated by decreased CD44 expression in splenic B cells
|
|
|
• serum IgG2a levels are decreased compared to Faslpr homozygotes
|
|
|
• serum IgG3 levels are decreased compared to Faslpr homozygotes
|
|
|
• lymph node weight is decreased compared to Faslpr homozygotes
|
|
|
• plasmacytoid DCs exhibit a more immature phenotype compared to Faslpr homozygotes, with decreased expression of MHC class II
|
|
|
• renal disease is significantly decreased compared to Faslpr homozygotes, with mice showing decreased glomerular protein deposition and preserved glomerular structure
• although skin disease is evident in mutants, it occurs with a very low frequency and very little is seen at 16 weeks of age
|
|
|
• mutants exhibit impaired generation of antibodies to RNA complexes and generation of high-titer Smith antibodies is blocked
|
|
|
• DNA autoantibodies are seen in mutants
|
hematopoietic system
|
|
• decrease in accumulation of double-negative T cells in the spleen compared to Faslpr homozygotes
|
|
|
• decrease in proportion of CD4+ T cells expressing CD44, both in the lymph node and spleen compared to Faslpr homozygotes
|
|
|
• spleen weight is decreased compared to Faslpr homozygotes
|
|
|
• general B cell activation is inhibited compared to Faslpr homozygotes, as indicated by decreased CD44 expression in splenic B cells
|
|
|
• serum IgG2a levels are decreased compared to Faslpr homozygotes
|
|
|
• serum IgG3 levels are decreased compared to Faslpr homozygotes
|


Analysis Tools